Women Struggle to Find Vital Menopause Medication

Women nationwide are facing an ongoing struggle to obtain essential estrogen patches for menopause symptom relief, as demand for hormone replacement therapy has dramatically increased. This surge follows the FDA's removal of a "black box warning" in February, making more women and doctors comfortable with its use. Prescriptions for estrogen patches saw a substantial rise, increasing from approximately 594,000 in June 2024 to 1.6 million by May 2026.

This heightened demand has outpaced supply, leading to difficulties in refilling prescriptions. Patients report stress and extensive efforts to find available medication, with some pharmacies unable to provide the full prescribed amounts. Doctors and patient advocacy groups are petitioning the FDA to officially declare a shortage. They argue this designation could encourage manufacturers to boost production and potentially attract new companies to the market.

Legislators have also called on the FDA to add estradiol patches to its drug shortage database, noting that the agency's reliance on historical demand data may not accurately reflect the rapid spike in need. The current situation is particularly frustrating for women who have navigated years of misinformation regarding hormone therapy and are now facing access issues for treatments that can also offer disease prevention benefits.

Patients are concerned about the impact of these shortages on their health and well-being, emphasizing that women's health needs require greater attention and acknowledgment.